Biota Pharma (BOTA) Doses First Patient in BTA074 5% Gel Phase 2 as Condyloma Treatment
Tweet Send to a Friend
Biota Pharmaceuticals, Inc. (Nasdaq: BOTA) announced that the first patient has been dosed in a Phase 2 double-blind, randomized, placebo-controlled ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
